Poor response to antidepressants predicts new suicidal ideas and behavior in depressed outpatients

European Neuropsychopharmacology

Volumn 24, Issue 10, 2014, Pages 1650-1658

  Courtet, Philippe ^a,b,c,d   Jaussent, Isabelle ^b,c   Lopez Castroman, Jorge ^a,b   Gorwood, Philip ^d,e,f  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM U1061   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

^e CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Depression; Outcome; Suicide attempt; Suicide ideation; Suicide risk; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; AGED; ANXIETY; ARTICLE; ATTRIBUTABLE RISK; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; FRANCE; HOPELESSNESS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; MULTIVARIATE ANALYSIS; OUTPATIENT; PREDICTION; PSYCHOPHARMACOTHERAPY; RISK FACTOR; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYMPTOM; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; DEPRESSIVE DISORDER; LONGITUDINAL STUDY; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908044111     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.07.007     Document Type: Article

References (42)

1. Beck A.T., et al. The measurement of pessimism: the hopelessness scale. J. Consult. Clin. Psychol. 1974, 42(6):861-865.
2. Bondolfi G., et al. Self- and clinician-rated Montgomery-Åsberg Depression Rating Scale: evaluation in clinical practice. J. Affect. Disord. 2010, 121(3):268-272.
3. Bouvard M., et al. Study of Beck[U+05F3]s hopelessness scale. validation and factor analysis. L'Encéphale 1992, 18(3):237-240.
4. Brent D.A. Selective serotonin reuptake inhibitors and suicidality: a guide for the perplexed. Can. J. Psychiatry Revue Canadienne de Psychiatrie 2009, 54(2):72-74. (discussion 75).
5. Brent D.A., Mann J.J. Family genetic studies, suicide, and suicidal behavior. Am. J. Med. Genet. Part B: Neuropsychiatric Genet. 2005, 133C(1):13-24.
6. Catalá-López F., Gènova-Maleras R., Vieta E., Tabarés-Seisdedos R. The increasing burden of mental and neurological disorders. Eur. Neuropsychopharmacol. 2013, 23(11):1337-1339.
7. Desseilles M., et al. Is it valid to measure suicidal ideation by depression rating scales?. J. Affect. Disord. 2011, 1-7.
8. Friedman S., et al. Three-dimensional structure of the Hospital Anxiety and Depression Scale in a large French primary care population suffering from major depression. Psychiatry Res. 2001, 104(3):247-257.
9. Gaynes B.N., et al. Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann. Family Med. 2007, 5(2):126-134.
10. Gibbons R.D., et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am. J. Psychiatry 2007, 164(9):1356-1363.
11. Gorwood P., et al. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am. J. Psychiatry 2008, 165(6):731-739.
12. Hamilton B.E., et al. Annual summary of vital statistics: 2005. Pediatrics 2007, 119(2):345-360.
13. Holma K.M., et al. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study. Am. J. Psychiatry 2010, 167(7):801-808.
14. Hosmer D.M., Lemeshow S. Applied Logistic Regression 2nd edition Wiley Series in Probability and Statistics 2000, John Wiley & Sons, Hoboken, New Jersey.
15. Isacsson G., et al. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. Acta Psychiatrica Scand. 2009, 120(1):37-44.
16. Katz L.Y., et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. Can. Med. Assoc. J. 2008, 178(8):1005-1011.
17. Laughren, T. ed., 2006. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Commitee (PDAC), Available at: [Accessed June 24, 2013]. http://www.fda.gov/OHRMS/.
18. Libby A.M., Orton H.D., Valuck R.J. Persisting decline in depression treatment after FDA warnings. Arch. Gen. Psychiatry 2009, 66(6):633-639.
19. Licinio J., Wong M.-L. Depression, antidepressants and suicidality: a critical appraisal. Nat. Rev. Drug Discov. 2005, 4(2):165-171.
20. Mann Suicide prevention strategies a systematic review. JAMA 2005, 294(16):2064-2074.
21. Mann J.J., et al. Toward a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry 1999, 156(2):181-189.
22. Mc Dowell I. Measuring Health: A Guide to Rating Scales and Questionnaires 2006, Oxford University Press, Inc., New York. 3rd Edition.
23. Meyer R.E., et al. Suicidality and risk of suicide - definition, drug safety concerns, and a necessary target for drug development. J. Clin. Psychiatry 2010, 71(08):e1-e21.
24. Mickey R.M., Greenland S. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 1989, 129:125-137.
25. Mulder R.T., et al. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatr. Scand. 2008, 118(2):116-122.
26. Nock M.K., et al. Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol. Psychiatry 2010, 15(8):868-876.
27. Oquendo M.A., et al. Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am. J. Psychiatry 2002, 159(10):1746-1751.
28. Oquendo M.A., et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am. J. Psychiatry 2004, 161(8):1433-1441.
29. Perlis R.H., et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother. Psychosom. 2007, 76(1):40-46.
30. Perroud N., et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med. 2009, 7:60.
31. Rihmer Z., Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J. Affect. Disord. 2006, 94(1-3):3-13.
32. Seemüller F., et al. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int. J. Neuropsychopharmacol. 2008, 12(02):181.
33. Silverman M.M., et al. Rebuilding the tower of Babel: a revised nomenclature for the study of suicide and suicidal behaviors. Part 1: background, rationale, and methodology. Suicide & Life-threat. Behav. 2007, 37(3):248-263.
34. Simon G.E., Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am. J. Psychiatry 2007, 164(7):1029-1034.
35. Stone M., et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009, 339(aug11 2). (Clinical research ed.), (b2880-b2880).
36. Svanborg P., Asberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J. Affect. Disord. 2001, 64(2-3):203-216.
37. Svanborg P., Asberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr. Scand. 1994, 89(1):21-28.
38. Szanto K., et al. Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. J. Affect. Disord. 2007, 98(1-2):153-161.
39. Tondo L., Lepri B., Baldessarini R.J. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiatr. Scand. 2008, 118(2):106-115.
40. Valuck R.J., et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am. J. Psychiatry 2007, 164(8):1198-1205.
41. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67(6):361-370.
42. Zisook S., et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR-D study. Am. J. Psychiatry 2009, 1-11.